Timothy Lee Lash

Timothy Lee Lash

Auto-generated profile, based on publicly available information

Timothy Lee Lash

From the Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2011 in BMC Medical Research Methodology
Verified
Journal Article
Open access
PDF file
STSandra K Thygesen
Sandra K Thygesen
CCChristian F Christiansen
Christian F Christiansen
SCSteffen Christensen
Steffen Christensen
TLTimothy L Lash
Timothy L Lash
Henrik Toft SørensenHenrik Toft Sørensen
Henrik Toft Sørensen
The Charlson comorbidity index is often used to control for confounding in research based on medical databases. There are few studies of the accuracy of the codes obtained from these databases.

30 July 2014 in International Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
TLTimothy L Lash
Timothy L Lash
MFMatthew P Fox
Matthew P Fox
RMRichard F MacLehose
Richard F MacLehose
GMGeorge Maldonado
George Maldonado
LMLawrence C McCandless
Lawrence C McCandless
SGSander Greenland
Sander Greenland
Quantitative bias analysis serves several objectives in epidemiological research. First, it provides a quantitative estimate of the direction, magnitude and uncertainty arising from systematic errors. Second, the acts of identifying sources of systematic error, writing down models to quantify them, assigning values to the bias parameters and interpreting the results combat the human tendency towards overconfidence in research results, syntheses and critiques and the inferences that rest upon them. Finally, by suggesting aspects that dominate uncertainty in a particular research result or topic area, bias analysis can guide efficient allocation of sparse research resources. The fundamental methods of bias analyses have been known for decades, and there have been calls for more widespread use for nearly as long. There was a time when some believed that bias analyses were rarely undertaken because the methods were not widely known and because automated computing tools were not readily available to implement the methods. These shortcomings have been largely resolved. We must, therefore, contemplate other barriers to implementation. One possibility is that practitioners avoid the analyses because they lack confidence in the practice of bias analysis. The purpose of this paper is therefore to describe what we view as good practices for applying quantitative bias analysis to epidemiological data, directed towards those familiar with the methods. We focus on answering questions often posed to those of us who advocate incorporation of bias analysis methods into teaching and research. These include the following. When is bias analysis practical and productive? How does one select the biases that ought to be addressed? How does one select a method to model biases? How does one assign values to the parameters of a bias model? How does one present and interpret a bias analysis?. We hope that our guide to good practices for conducting and presenting bias analyses will encourage more widespread use of bias analysis to estimate the potential magnitude and direction of biases, as well as the uncertainty in estimates potentially influenced by the biases.

8 November 2021 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
RPRikke Nørgaard Pedersen
Rikke Nørgaard Pedersen
BEBuket Öztürk Esen
Buket Öztürk Esen
LMLene Mellemkjær
Lene Mellemkjær
PCPeer Christiansen
Peer Christiansen
BEBent Ejlertsen
Bent Ejlertsen
DCDeirdre Cronin-Fenton
Deirdre Cronin-Fenton
Background: Extended, more effective breast cancer treatments have increased the prevalence of long-term survivors. We investigated the risk of late breast cancer recurrence (BCR), 10 years or more after primary diagnosis, and associations between patient and tumor characteristics at primary diagnosis and late BCR up to 32 years after primary breast cancer diagnosis. Methods: Using the Danish Breast Cancer Group clinical database, we identified all women with an incident early breast cancer diagnosed during 1987-2004. We restricted to women who survived 10 years without a recurrence or second cancer (10-year disease-free survivors) and followed them from 10 years after breast cancer diagnosis date until late recurrence, death, emigration, second cancer, or December 31, 2018. We calculated incidence rates per 1000 person-years and cumulative incidences for late BCR, stratifying by patient and tumor characteristics. Using Cox regression, we calculated adjusted hazard ratios for late BCR accounting for competing risks. Results: Among 36 924 women with breast cancer, 20 315 became 10-year disease-free survivors. Of these, 2595 developed late BCR (incidence rate = 15.53 per 1000 person-years, 95% confidence interval = 14.94 to 16.14; cumulative incidence = 16.6%, 95% confidence interval = 15.8% to 17.5%) from year 10 to 32 after primary diagnosis. Tumor size larger than 20 mm, lymph node–positive disease, and estrogen receptor–positive tumors were associated with increased cumulative incidences and hazards for late BCR. Conclusions: Recurrences continued to occur up to 32 years after primary diagnosis. Women with high lymph node burden, large tumor size, and estrogen receptor–positive tumors had increased risk of late recurrence. Such patients may warrant extended surveillance, more aggressive treatment, or new therapy approaches.

22 August 2017 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
TLTimothy L. Lash
Timothy L. Lash
In the last few years, stakeholders in the scientific community have raised alarms about a perceived lack of reproducibility of scientific results. In reaction, guidelines for journals have been promulgated and grant applicants have been asked to address the rigor and reproducibility of their proposed projects. Neither solution addresses a primary culprit, which is the culture of null hypothesis significance testing that dominates statistical analysis and inference. In an innovative research enterprise, selection of results for further evaluation based on null hypothesis significance testing is doomed to yield a low proportion of reproducible results and a high proportion of effects that are initially overestimated. In addition, the culture of null hypothesis significance testing discourages quantitative adjustments to account for systematic errors and quantitative incorporation of prior information. These strategies would otherwise improve reproducibility and have not been previously proposed in the widely cited literature on this topic. Without discarding the culture of null hypothesis significance testing and implementing these alternative methods for statistical analysis and inference, all other strategies for improving reproducibility will yield marginal gains at best.

1 May 2021 in Annals of Internal Medicine
Verified
Journal Article
Open access
JBJulia M Baker
Julia M Baker
KNKristin N. Nelson
Kristin N. Nelson
EOElizabeth Overton
Elizabeth Overton
BLBenjamin A. Lopman
Benjamin A. Lopman
TLTimothy L. Lash
Timothy L. Lash
JSJames P. Steinberg
James P. Steinberg
It is critical to determine how best to prevent SARS-CoV-2 infection in health care workers. Early in the pandemic, a voluntary survey of such workers coupled with serologic testing were used to as... Background: Identifying occupational risk factors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among health care workers (HCWs) can improve HCW and patient safety. Obj...

15 February 2011 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
TLTimothy L. Lash
Timothy L. Lash
DCDeirdre Cronin-Fenton
Deirdre Cronin-Fenton
TAThomas P. Ahern
Thomas P. Ahern
CRCarol L. Rosenberg
Carol L. Rosenberg
KLKathryn L. Lunetta
Kathryn L. Lunetta
SHStephen Jacques Hamilton-Dutoit
Stephen Jacques Hamilton-Dutoit
Cytochrome P450 2D6 (CYP2D6) inhibition reduces the concentration of 4-hydroxylated tamoxifen metabolites, but the clinical relevance remains uncertain. We conducted a large case–control study nested in the population of 11 251 women aged 35–69 years at diagnosis of stage I–III breast cancer between 1985 and 2001 on Denmark’s Jutland Peninsula and registered with the Danish Breast Cancer Cooperative Group. We identified 541 recurrent or contralateral breast cancers among women with estrogen receptor–positive (ER+) disease treated with tamoxifen for at least 1 year and 300 cancers in women with ER-negative (ER−) disease never treated with tamoxifen. We matched one control subject per case patient on ER status, menopausal status, stage, calendar time, and county, genotyped the CYP2D6*4 allele to assess genetic inhibition, and ascertained prescription history to assess drug–drug inhibition. We estimated the odds ratio (OR), associating CYP2D6 inhibition with breast cancer recurrence and adjusted for potential confounding with logistic regression. To address bias from incomplete information on CYP2D6 function, we used Monte Carlo simulation to complete a record-level probabilistic bias analysis. All statistical tests were two-sided. The frequency of the CYP2D6*4 minor allele was 24% in case patients with ER+ tumors, 23% in case patients with ER− tumors, and 22% each in control subjects with ER+ and ER− tumors. In women with ER+ tumors, the associations of one functional allele with recurrence (OR = 0.99; 95% confidence interval = 0.76 to 1.3) and no functional allele with recurrence (OR = 1.4; 95% confidence interval = 0.84 to 2.3) were near null, as were those for women with ER− tumors. The near-null associations persisted when evaluated by intake of medications, by combining genotype with medication history, in the probabilistic bias analysis, or by restricting the analysis to women with ER expression confirmed by re-assay. The association between CYP2D6 inhibition and recurrence in tamoxifen-treated patients is likely null or small.